Home > Dermatology > AAD 2020 > IL-13 blocker tralokinumab effective in AD

IL-13 blocker tralokinumab effective in AD

IL-13 plays a key role in pathogenesis of atopic dermatitis (AD). The phase 3 ECZTRA trials demonstrated the remarkable efficacy of the IL-13 blocker tralokinumab in adult patients with moderate-to-severe AD [1].

AD is a chronic inflammatory skin disease. Tralokinumab is a fully human monoclonal antibody designed specifically to neutralise IL-13, a key driver of the underlying inflammation in AD, as Prof. Eric Simpson (Oregon Health & Science University, USA) explained. Recent data has suggested that IL-13 is the key type-2 cytokine driving inflammation in the periphery: IL-13 is overexpressed locally and has a significant impact on skin biology, including the recruitment of inflammatory cells, the alteration of the skin microbiome, and the decrease in the epidermal barrier function [2].

In the randomised, placebo-controlled, multinational phase 3 ECZTRA 1 and



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on